JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6
JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
Read original at benzingaStocks · News reference
Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75
Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 23, 2026, 11:25 AM
- Checked
- Jul 23, 2026, 11:25 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6
TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
Read original at benzingaTiger Global Management Increases Stake In Evolent Health Inc By 99% To 11,063,912 Shares
Read original at benzingaTruist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.
Read original at benzinga